Drug Safety Update: Brimonidine gel (Mirvaso): risk of exacerbation of rosacea

The Medicines and Healthcare products Regulatory Agency (MHRA) have produced a drug safety update for the use of Brimonidine (Mirvaso) to highlight that symptom exacerbation has been reported very com
Source: Royal Pharmaceutical Society News - Category: Drugs & Pharmacology Source Type: news